The most common grade 3 or higher adverse events (AEs) included neutropenia (94%), thrombocytopenia (65%), and anemia (35%), which confirm that GPRC5D is an active immunotherapeutic target in multiple myeloma [229, 254]. Here, GPRC5D is linked to plasma cell myeloma.